Molecular Insights Into the Pathogenesis of Follicular Lymphoma
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
IRF4/DUSP22 Gene Rearrangement by FISH
IRF4/DUSP22 Gene Rearrangement by FISH The IRF4/DUSP22 locus is rearranged in a newly recognized subtype of non-Hodgkin lymphoma, large B-cell lymphoma with IRF4 rearrangement. These lymphomas are uncommon, but are clinically distinct from morphologically similar lymphomas, Tests to Consider including diffuse large B-cell lymphoma, high-grade follicular lymphoma, and pediatric- type follicular lymphoma. The IRF4/DUSP22 locus is also rearranged in a subset of ALK- IRF4/DUSP22 (6p25) Gene Rearrangement negative anaplastic large cell lymphomas (ALCL), where this rearrangement is associated by FISH 3001568 with a signicantly better prognosis. Method: Fluorescence in situ Hybridization (FISH) Test is useful in identifying ALK-negative anaplastic large cell lymphomas and large B- Disease Overview cell lymphoma with IRF4 rearrangement The rearrangement is associated with an improved prognosis Incidence See Related Tests Large B-cell lymphoma with IRF4 rearrangement accounts for <1% of all non-Hodgkin B-cell lymphomas overall More common in younger patients, with an incidence of 5-6% under age 18 IRF4/DUSP22 rearrangement is found in 30% of ALK-negative ALCLs Symptoms/Findings Large B-cell lymphoma with IRF4 rearrangement typically presents with limited stage disease in the head and neck, while the presentation of ALK-negative ALCLs is variable. Disease-Oriented Information Patients with large B-cell lymphoma with IRF4 rearrangement typically have a favorable outcome after treatment. Rearrangement of the IRF4/DUSP22 locus in ALK-negative ALCL is associated with a better prognosis than ALK-negative ALCL without this rearrangement. Test Interpretation Analytical Sensitivity The limit of detection (LOD) for the IRF4/DUSP22 probe was established by calculating the upper limit of the abnormal signal pattern in normal cells using the Microsoft Excel BETAINV function. -
Follicular Lymphoma
Follicular Lymphoma What is follicular lymphoma? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines FOLLICULAR LYMPHOMA: A GUIDE FOR PATIENTS PATIENT INFORMATION BASED ON ESMO CLINICAL PRACTICE GUIDELINES This guide for patients has been prepared by the Anticancer Fund as a service to patients, to help patients and their relatives better understand the nature of follicular lymphoma and appreciate the best treatment choices available according to the subtype of follicular lymphoma. We recommend that patients ask their doctors about what tests or types of treatments are needed for their type and stage of disease. The medical information described in this document is based on the clinical practice guidelines of the European Society for Medical Oncology (ESMO) for the management of newly diagnosed and relapsed follicular lymphoma. This guide for patients has been produced in collaboration with ESMO and is disseminated with the permission of ESMO. It has been written by a medical doctor and reviewed by two oncologists from ESMO including the lead author of the clinical practice guidelines for professionals, as well as two oncology nurses from the European Oncology Nursing Society (EONS). It has also been reviewed by patient representatives from ESMO’s Cancer Patient Working Group. More information about the Anticancer Fund: www.anticancerfund.org More information about the European Society for Medical Oncology: www.esmo.org For words marked with an asterisk, a definition is provided at the end of the document. Follicular Lymphoma: a guide for patients - Information based on ESMO Clinical Practice Guidelines – v.2014.1 Page 1 This document is provided by the Anticancer Fund with the permission of ESMO. -
The Lymphoma and Multiple Myeloma Center
The Lymphoma and Multiple Myeloma Center What Sets Us Apart We provide multidisciplinary • Experienced, nationally and internationally recognized physicians dedicated exclusively to treating patients with lymphoid treatment for optimal survival or plasma cell malignancies and quality of life for patients • Cellular therapies such as Chimeric Antigen T-Cell (CAR T) therapy for relapsed/refractory disease with all types and stages of • Specialized diagnostic laboratories—flow cytometry, cytogenetics, and molecular diagnostic facilities—focusing on the latest testing lymphoma, chronic lymphocytic that identifies patients with high-risk lymphoid malignancies or plasma cell dyscrasias, which require more aggresive treatment leukemia, multiple myeloma and • Novel targeted therapies or intensified regimens based on the other plasma cell disorders. cancer’s genetic and molecular profile • Transplant & Cellular Therapy program ranked among the top 10% nationally in patient outcomes for allogeneic transplant • Clinical trials that offer tomorrow’s treatments today www.roswellpark.org/partners-in-practice Partners In Practice medical information for physicians by physicians We want to give every patient their very best chance for cure, and that means choosing Roswell Park Pathology—Taking the best and Diagnosis to a New Level “ optimal front-line Lymphoma and myeloma are a diverse and heterogeneous group of treatment.” malignancies. Lymphoid malignancy classification currently includes nearly 60 different variants, each with distinct pathophysiology, clinical behavior, response to treatment and prognosis. Our diagnostic approach in hematopathology includes the comprehensive examination of lymph node, bone marrow, blood and other extranodal and extramedullary tissue samples, and integrates clinical and diagnostic information, using a complex array of diagnostics from the following support laboratories: • Bone marrow laboratory — Francisco J. -
Immunodeficiency Patients Differentiation of Common Variable
Defined Blocks in Terminal Plasma Cell Differentiation of Common Variable Immunodeficiency Patients This information is current as Nadine Taubenheim, Marcus von Hornung, Anne Durandy, of September 24, 2021. Klaus Warnatz, Lynn Corcoran, Hans-Hartmut Peter and Hermann Eibel J Immunol 2005; 175:5498-5503; ; doi: 10.4049/jimmunol.175.8.5498 http://www.jimmunol.org/content/175/8/5498 Downloaded from References This article cites 35 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/175/8/5498.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Defined Blocks in Terminal Plasma Cell Differentiation of Common Variable Immunodeficiency Patients1 Nadine Taubenheim,* Marcus von Hornung,* Anne Durandy,† Klaus Warnatz,‡ Lynn Corcoran,§ Hans-Hartmut Peter,‡ and Hermann Eibel2* Common variable immunodeficiency (CVID) is a heterogeneous disorder characterized by defective Ab production and recurrent bacterial infections. -
Laboratory Mouse Models for the Human Genome-Wide Associations
Laboratory Mouse Models for the Human Genome-Wide Associations The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Kitsios, Georgios D., Navdeep Tangri, Peter J. Castaldi, and John P. A. Ioannidis. 2010. Laboratory mouse models for the human genome-wide associations. PLoS ONE 5(11): e13782. Published Version doi:10.1371/journal.pone.0013782 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:8592157 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Laboratory Mouse Models for the Human Genome-Wide Associations Georgios D. Kitsios1,4, Navdeep Tangri1,6, Peter J. Castaldi1,2,4,5, John P. A. Ioannidis1,2,3,4,5,7,8* 1 Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, United States of America, 2 Tufts University School of Medicine, Boston, Massachusetts, United States of America, 3 Department of Hygiene and Epidemiology, University of Ioannina School of Medicine and Biomedical Research Institute, Foundation for Research and Technology-Hellas, Ioannina, Greece, 4 Tufts Clinical and Translational Science Institute, Tufts Medical Center, Boston, Massachusetts, United States of America, 5 Department of Medicine, Center for Genetic Epidemiology and Modeling, Tufts Medical Center, Tufts University -
Evaluation of the Effects of Activation Dependent Regulation of Cd40l on Germinal Center Response Using Cd40lδ5 Mouse Model
EVALUATION OF THE EFFECTS OF ACTIVATION DEPENDENT REGULATION OF CD40L ON GERMINAL CENTER RESPONSE USING CD40LΔ5 MOUSE MODEL By BITHA NARAYANAN A dissertation submitted to the School of Graduate Studies Rutgers, The State University of New Jersey In partial fulfillment of the requirements For the degree of Doctor of Philosophy Graduate Program in Microbiology and Molecular Genetics written under the direction of Lori R. Covey and approved by _____________________________________ _____________________________________ _____________________________________ _____________________________________ New Brunswick, New Jersey January 2020 ©[2020] Bitha Narayanan ALL RIGHTS RESERVED ABSTRACT OF THE DISSERTATION ACTIVATION-DEPENDENT POSTTRANSCRIPTIONAL REGULATION OF CD40L IS REQUIRED FOR AN OPTIMAL GERMINAL CENTER (GC) RESPONSE. by BITHA NARAYANAN Dissertation Director Dr. Lori R. Covey The interaction between cognate T and B cells decides the progression of an immune response to a pathogen or self-antigen. Of the multiple signals that synchronize to fine-tune this union, the binding of CD40 on the surface of B cells to CD40L expressed on CD4 T cells is of paramount importance. Ligation of CD40 on antigen- experienced B cells is associated with the initiation and development of germinal centers (GCs) resulting in the subsequent generation of high affinity antibodies and B cell memory. Post-transcriptional regulation of CD40L has been implicated in regulating the activation dependent expression of this protein. Our lab has previously shown a polypyrimidine tract binding protein complex binds to the 3’ UTR of the CD40L mRNA ii and that the deletion of a PTBP1 binding stability element in the same results in a significant decrease in the half-life of the CD40L transcript and subsequently the surface expression at later stages of activation in vitro. -
Does Recycling in Germinal Centers Exist?
Does Recycling in Germinal Centers Exist? Michael Meyer-Hermann Institut f¨ur Theoretische Physik, TU Dresden, D-01062 Dresden, Germany E-Mail: [email protected] Abstract: A general criterion is formulated in order to decide if recycling of B-cells exists in GC reactions. The criterion is independent of the selection and affinity maturation process and based solely on total centroblast population arguments. An experimental test is proposed to verify whether the criterion is fulfilled. arXiv:physics/0102062v2 [physics.bio-ph] 6 Mar 2002 1 1 Introduction The affinity maturation process in germinal center (GC) reactions has been well charac- terized in the last decade. Despite a lot of progress concerning the morphology of GCs and the stages of the selection process, a fundamental question remains unsolved: Does recycling exist? Recycling means a back differentiation of antibody presenting centrocytes (which undergo the selection process and interact with antigen fragments or T-cells) to centroblasts (which do not present antibodies and therefore do not interact with antigen fragments but proliferate and mutate). The existence of recycling in the GC has important consequences for the structure of the affinity maturation process in GC reactions. The centroblasts proliferate and mutate with high rates in the environment of follicular dendritic cells. During the GC reaction they differentiate to antibody presenting centrocytes which may then be selected by inter- action with antigen fragments and T-cells. If the positively selected centrocytes recycle to (proliferating and mutating) centroblasts the antibody-optimization process in GCs may be compatible with random mutations of the centroblasts. -
The Lymphoma Guide Information for Patients and Caregivers
The Lymphoma Guide Information for Patients and Caregivers Ashton, lymphoma survivor This publication was supported by Revised 2016 Publication Update The Lymphoma Guide: Information for Patients and Caregivers The Leukemia & Lymphoma Society wants you to have the most up-to-date information about blood cancer treatment. See below for important new information that was not available at the time this publication was printed. In November 2017, the Food and Drug Administration (FDA) approved obinutuzumab (Gazyva®) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). In November 2017, the Food and Drug Administration (FDA) approved brentuximab vedotin (Adcetris®) for treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30- expressing mycosis fungoides (MF) who have received prior systemic therapy. In October 2017, the Food and Drug Administration (FDA) approved acalabrutinib (CalquenceTM) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. In October 2017, the Food and Drug Administration (FDA) approved axicabtagene ciloleucel (Yescarta™) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Yescarta is a CD19-directed genetically modified autologous T cell immunotherapy FDA approved. Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. In September 2017, the Food and Drug Administration (FDA) approved copanlisib (AliqopaTM) for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. -
In Situ Observation of Germinal Center Cell Apoptosis During a Secondary Immune Response
J Clin Exp Hematopathol Vol. 46, No. 2, Nov 2006 Original Article In Situ Observation of Germinal Center Cell Apoptosis During a Secondary Immune Response Hito-aki Saitoh, Kunihiko Maeda, and Mitsunori Yamakawa Germinal centers are highly organized anatomic structures essential for the clonal expansion of germinal center (GC) B- cells and associated somatic hypermutation, isotype switching, selection of the high-affinity B-cells (affinity maturation), and elimination of irrelevant or autoreactive clones. The identification of cellular interactions and regulatory mechanisms controlling apoptosis within GCs is essential for a complete understanding of the cellular and molecular dynamics of the GC reaction. We performed a kinetic analysis of the apoptotic activity occurring within GCs of draining lymph nodes of mice immunized with sheep red blood cells (SRBC) after secondary stimulation. The apoptotic activity of GC cells can be divided into three distinct phases : 1) initial phase (within the first days after immunization), 2) reactive phase (from the 5th day to 15th day after secondary immunization), and 3) late phase (after the 15th day). Apoptosis decreased shortly after secondary immunization followed by an increase to peak after an additional 10 days. Finally, apoptosis of GC cells decreased to basal levels. Administration of apoptosis inhibitors decreased the amount of apoptosis during the reactive phase. These results suggest that the reactive phase may be the critical period in which clonal selection and cellular differentiation -
The UBE2L3 Ubiquitin Conjugating Enzyme: Interplay with Inflammasome Signalling and Bacterial Ubiquitin Ligases
The UBE2L3 ubiquitin conjugating enzyme: interplay with inflammasome signalling and bacterial ubiquitin ligases Matthew James George Eldridge 2018 Imperial College London Department of Medicine Submitted to Imperial College London for the degree of Doctor of Philosophy 1 Abstract Inflammasome-controlled immune responses such as IL-1β release and pyroptosis play key roles in antimicrobial immunity and are heavily implicated in multiple hereditary autoimmune diseases. Despite extensive knowledge of the mechanisms regulating inflammasome activation, many downstream responses remain poorly understood or uncharacterised. The cysteine protease caspase-1 is the executor of inflammasome responses, therefore identifying and characterising its substrates is vital for better understanding of inflammasome-mediated effector mechanisms. Using unbiased proteomics, the Shenoy grouped identified the ubiquitin conjugating enzyme UBE2L3 as a target of caspase-1. In this work, I have confirmed UBE2L3 as an indirect target of caspase-1 and characterised its role in inflammasomes-mediated immune responses. I show that UBE2L3 functions in the negative regulation of cellular pro-IL-1 via the ubiquitin- proteasome system. Following inflammatory stimuli, UBE2L3 assists in the ubiquitylation and degradation of newly produced pro-IL-1. However, in response to caspase-1 activation, UBE2L3 is itself targeted for degradation by the proteasome in a caspase-1-dependent manner, thereby liberating an additional pool of IL-1 which may be processed and released. UBE2L3 therefore acts a molecular rheostat, conferring caspase-1 an additional level of control over this potent cytokine, ensuring that it is efficiently secreted only in appropriate circumstances. These findings on UBE2L3 have implications for IL-1- driven pathology in hereditary fever syndromes, and autoinflammatory conditions associated with UBE2L3 polymorphisms. -
Lymph Node Cytology
Lymph node cytopathology : A practical approach to lymphoproliferative disorders • Koray Ceyhan, M.D • Department of Pathology • Faculty of Medicine • Ankara University • Ankara, Turkey Diagnostic use of FNA in lymph node pathologies • Well-established : • - metastatic malignancy, • - lymphoma recurrences • -some reactive or inflammatory disorders: Tuberculosis,sarcoidosis • Diagnostic sensitivity/accuracy : usually above 95% • Controversial: • primary lymphoma diagnosis • Diagnostic sensitivity varies from 12% to 96% Academic institutions: high level diagnostic accuracy Community practise the accuracy rate significantly low Multiparameter approach is critical for definitive lymphoma diagnosis • Cytomorphologic features alone are not sufficient for the diagnosis of primary lymphoma • Immunophenotyping with flow cytometry and/or immunocytochemistry is mandatory • In selected cases molecular/cytogenetic analyses are required for definitive lymphoma classification Lymph node pathologies • 1-Reactive lymphoid hyperplasia/inflammatory disorders • 2-Lymphoid malignancies • 3-Metastatic tumors 1 3 2 Common problems in lymph node cytology • Reactive lymphoid hyperplasia vs lymphoma • Primary lymphoma diagnosis(lymphoma subtyping) • Predicting primary site of metastatic tumor • Nonlymphoid tumors mimicking lymphoid malignancies • Correct diagnosis of specific benign lymphoid lesions Problem 1: Reactive vs lymphoma Case 19- years-old boy Multiple bilateral cervical LAPs for 4 weeks FNA from the largest cervical lymph node measuring 15X13 mm No -
Efficient Analysis of Mouse Genome Sequences Reveal Many Nonsense Variants
Efficient analysis of mouse genome sequences reveal many nonsense variants Sophie Steelanda,b,1, Steven Timmermansa,b,1, Sara Van Ryckeghema,b, Paco Hulpiaua,b, Yvan Saeysa,c, Marc Van Montagud,e,f,2, Roosmarijn E. Vandenbrouckea,b,3, and Claude Liberta,b,2,3 aInflammation Research Center, Flanders Institute for Biotechnology (VIB), 9052 Ghent, Belgium; bDepartment of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium; cDepartment of Internal Medicine, Ghent University, 9052 Ghent, Belgium; dDepartment of Plant Systems Biology, VIB, 9052 Ghent, Belgium; eDepartment of Plant Biotechnology and Bioinformatics, Ghent University, 9052 Ghent, Belgium; and fInternational Plant Biotechnology Outreach, VIB, Ghent, Belgium Contributed by Marc Van Montagu, March 30, 2016 (sent for review December 31, 2015; reviewed by Bruce Beutler, Stefano Bruscoli, Stefan Rose-John, and Klaus Schulze-Osthoff) Genetic polymorphisms in coding genes play an important role alive, archiving them, and distributing mutant strains to in- when using mouse inbred strains as research models. They have terested users (4). been shown to influence research results, explain phenotypical Since Clarence Little showed in the early 20th century that the differences between inbred strains, and increase the amount of principle of inbreeding also applies to mice, several hundred interesting gene variants present in the many available inbred inbred mouse strains have been generated (5). Some of these lines. SPRET/Ei is an inbred strain derived from Mus spretus that strains display specific phenotypes that are the result of a mutant has ∼1% sequence difference with the C57BL/6J reference ge- gene, and in several cases have formed the basis for identifying nome.